Vignette Bio
Industry
- Biotechnology
- Large Molecule
- Antibodies
- Large Molecule
- Pharmaceuticals
See more in Biomedtracker
Latest on Vignette Bio
In Vivo
• By Amanda Micklus
A key indicator of the strength of the biopharma industry is the health of new company creation. By reviewing Series A financing announced in 2024 as a proxy, In Vivo once again takes measurement of
Scrip
• By Amanda Micklus
One key indicator of the health of the biopharma industry is the rate of new company creation, and a new Evaluate analysis, using series A financings as a proxy shows that 2024 saw an encouraging up